Abcam, ab263331, Human RNF41 (NRDP1) knockout HeLa cell lysate

Size: 1Kit
RNF41 KO cell lysate available now. KO validated by. Free of charge wild type control included. Knockout achieved by using CRISPR/Cas9, 1 bp deletion in exon4.
Key facts
Cell type:HeLa,
Species or organism:Human,
Tissue:Cervix,
Knockout validation:Sanger Sequencing,
Mutation description:Knockout achieved by using CRISPR/Cas9, 1 bp deletion in exon4.,
Disease:Adenocarcinoma

Product details:
Knockout cell lysate achieved by CRISPR/Cas9.
REACH authorisation
Abcam has not and does not intend to apply for the REACH Authorisation of customers' uses of products that contain European Authorisation list (Annex XIV) substances.
It is the responsibility of our customers to check the necessity of application of REACH Authorisation, and any other relevant authorisations, for their intended uses.
Lysate preparation:
Our lysates are made using RIPA buffer to which we add a protease inhibitor cocktail and phosphatase inhibitor cocktail (ratio: 300:100:10).
This means that the protein of interest is denatured.
If you require a native form of the protein please use the live cell version. Please refer to our lysis protocol for further details on how our lysates are prepared.
User storage instructions:
Lyophilizate may be stored at 4°C. After reconstitution, store at -20°C for short-term storage or -80°C for long-term storage.
This product is subject to limited use licenses from The Broad Institute and ERS Genomics Limited, and is developed with patented technology. For full details of the limited use licenses and relevant patents please refer to our
limited use license
patent pages

Properties and Storage Information:
Gene name-RNF41, Gene editing type-Knockout, Gene editing method-CRISPR technology, Knockout validation-Sanger Sequencing, Shipped at conditions-Ambient - Can Ship with Ice, Appropriate short-term storage conditions--20°C, Appropriate long-term storage conditions--20°C

Supplementary Information:
This supplementary information is collated from multiple sources and compiled automatically.
NRDP1 also known as Neuregulin Receptor Degradation Protein 1 or FLJ11239 acts as an E3 ubiquitin ligase. It is a critical component for targeting certain proteins for ubiquitination and degradation processes. The protein has a molecular weight of approximately 36 kDa. Researchers have observed its expression in various tissues such as the brain heart and liver indicating its diverse role across different organ systems.
Biological function summary
NRDP1 functions in regulating protein levels within cells by tagging them for degradation. It particularly associates with ErbB3 a member of the epidermal growth factor receptor (EGFR) family and induces its ubiquitination. This interaction reflects NRDP1’s role in controlling cell proliferation signaling. It is not part of any multiprotein complex but has shown the capacity to influence individual protein interactions.
Pathways
Researchers identify NRDP1 as a participant in the ubiquitin-proteasome pathway and the ErbB signaling pathway. In the ubiquitin-proteasome pathway it facilitates the degradation of proteins to maintain cellular proteostasis. NRDP1 interacts with Parkin an E3 ubiquitin ligase associated with mitochondrial quality control. In the ErbB signaling pathway it modulates the function of ErbB receptors impacting cellular responses such as growth and differentiation.
NRDP1 is implicated in cancer and neurodegenerative diseases. Its dysregulation may lead to improper ErbB3 signaling contributing to the development of certain cancers. Abnormal NRDP1 function correlates with neurodegenerative diseases like Parkinson's disease where it interacts with Parkin. These interactions suggest that NRDP1’s role in proteostasis and cell signaling can influence disease progression.